Screener
Kymera Therapeutics KYMR Restricted Cash
Restricted Cash at other companies
Other financials
Where this comes from
Reported directly by Kymera Therapeutics in its filing.
Tagged under the XBRL concept us-gaap:RestrictedCashNoncurrent.
The source filing: Kymera Therapeutics’s 10-Q, filed August 5, 2026.
- Filed
- Aug 5, 2026, 7:15 AM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001193125-26-333849
| Line item | June 30,2026 | December 31,2025 |
|---|---|---|
| Property and equipment, net (Note 6) | 39,971 | 43,175 |
| Right-of-use assets, operating leases | 41,100 | 42,351 |
| Other non-current assets | 7,385 | 9,114 |
| Restricted cash | 5,822 | 5,800 |
| Total assets | $1,645,444 | $1,742,812 |
| Liabilities and Stockholders’ Equity | ||
| Current liabilities: | ||
| Accounts payable | $8,918 | $4,015 |
Item 1. Financial Statements.
FAQ
- What is Kymera Therapeutics's restricted cash?
- Kymera Therapeutics (KYMR) reported restricted cash of $5.82M in Q2 2026.
- How has Kymera Therapeutics's restricted cash changed year-over-year?
- Kymera Therapeutics's restricted cash increased by 0.0% year-over-year, from $5.82M to $5.82M.
- What is the long-term trend for Kymera Therapeutics's restricted cash?
- Over 5 years (2020 to 2025), Kymera Therapeutics's restricted cash has grown at a 29.6% compound annual growth rate (CAGR), from $1.59M to $5.8M.
- What does restricted cash mean?
- Cash restricted for specific purposes by contractual, regulatory, or legal requirements — not available for general corporate use.
Ask your AI about Kymera Therapeutics's restricted cash.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude